In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PTC Therapeutics, Inc.

http://www.ptcbio.com/

Latest From PTC Therapeutics, Inc.

10 Clinical Trials To Watch Out For In 2023

Scrip surveys the Phase III clinical trial readout landscape and picks 10 of the more interesting studies set to report in 2023, with a few added extras. AstraZeneca, Novo Nordisk, Novartis and Roche feature heavily.

Scrip Perspectives Clinical Trials

Improved Commercial Deal Helps PTC Win English Funding For Duchenne Drug

PTC Therapeutics has managed to convince England’s health technology assessment institute to reverse its recommendation against routine commissioning for Translarna.

United Kingdom Cost Effectiveness

Orphans Account For More Than A Third Of EU New Drug Approvals In 2022

Last year, the European Commission approved a record 55 therapies containing a new active substance, including 21 medicines for rare diseases. Among them were a number of gene therapies for indications such as cancer and hemophilia.

Europe Approvals

In Vivo’s Deals Of The Year: Cast Your Vote!

It is time for In Vivo's 15th annual Deals of the Year contest. We've selected 15 nominees across three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.

Deals Financing
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Other Names / Subsidiaries
    • Agilis Biotherapeutics, Inc.
    • Censa Pharmaceuticals Inc.
UsernamePublicRestriction

Register